Waltham, Massachusetts - (BUSINESS WIRE) -; (American business information) -- PerkinElmer (New York Stock Exchange code: PKI) (“ PerkinElmer”) announced today that it has reached an agreement to acquire BioLegend, a global provider of life science antibodies and reagents, with a cash and stock portfolio of about 5.25 billion dollars, but some adjustments are required
BioLegend provides its academic and biopharmaceutical customers with first-class antibodies and reagents for high growth fields such as cell counting, protein Genomics, multiple analysis, recombinant proteins, magnetic cell separation and biological processing. This transaction will be a transaction in PerkinElmer's history and is expected to be completed by the end of calendar year 2021, depending on regulatory approval and other customary closing conditions
Private BioLegend has over 700 employees, mainly in the United States, with an estimated revenue of $380 million in 2022. After joining PerkinElmer, BioLegend will expand PerkinElmer's existing life science franchise to new areas. Its advanced park located in San Diego, California will become PerkinElmer's Global Center of Excellence (CoE), developing research reagent content for the merged company
Prahlad Singh, President and CEO of PerkinElmer, commented on the agreement to acquire BioLegend and said:; We are delighted to have the opportunity to combine our technology and innovation culture, create seamless solutions, and drive the advancement of science and discovery. We believe that joining our team provides a rare opportunity to accelerate discovery and help life science researchers better understand and combat diseases by utilizing constantly evolving technologies and new methods.”
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinical doctors to address the most critical challenges they face in the fields of science and healthcare. Our mission is focused on innovating for a healthier world, providing unique solutions to serve the diagnostic, life sciences, food, and application markets. We engage in strategic cooperation with clients, supported by deep market knowledge and technical expertise, to provide earlier and more accurate insights. Our dedicated team of approximately 14000 employees worldwide is dedicated to helping customers strive to create healthier families, improve quality of life, and maintain the well-being and longevity of people worldwide. The company reported revenue of approximately $3.8 billion in 2020, serving customers in 190 countries/regions, and is a component of the S&P 500 Index. More information can be obtained through 1-877-PKI-NYSE at www.perkinelmer.com
